Scaling plasmid DNA production: A proven strategy for higher yields
As gene therapy programs move from proof of concept to commercial manufacturing, the pressure to deliver consistent, high-yield plasmid DNA (pDNA) has never been greater. In AAV-based workflows, plasmid quality is more than a starting material–it is the foundation for reliable transfection, efficient viral packaging, and predictable vector performance at scale.
Yet upstream challenges such as nutrient limitations, metabolic stress, acetate accumulation, and scale-up variability can compromise yield, supercoiled DNA content, and process reproducibility.
In this white paper, explore how Gibco™ animal-origin–free (AOF) peptones help overcome these barriers. By providing metabolically accessible peptides and amino acids, Gibco™ peptones support robust E. coli growth, improve plasmid titers, and enable smoother scale translation from development through production. Backed by collaborative case study data, learn how optimized peptone supplementation delivered significant yield improvements while maintaining plasmid integrity–and successfully translated from 5 L to 200 L scale.
Download the white paper to discover how integrating Gibco™ peptones into your upstream strategy can help you build a more resilient, scalable pDNA platform–strengthening the foundation of your AAV manufacturing process.
